Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer

Rajita Vatapalli(AstraZeneca (United States)), Sarki A. Abdulkadir(Robert H. Lurie Comprehensive Cancer Center of Northwestern University)

Nature Communications

August 19, 2020

10.1038/s41467-020-18013-7

Cited by 109

Related Papers

‘Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting

|British Journal of Cancer|2023|23

Asparagine Dependency Is a Targetable Metabolic Vulnerability in <i>TP53</i> -Altered Castration-Resistant Prostate Cancer

|Cancer Research|2024|22

Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B‐lineage acute lymphoblastic leukemia: A report of 1021 patients from India

|Cancer|2023|14

Identification and validation of the optimal reference genes for standardizing the gene expression profiling diagnostic panel of Ph-like B-lineage acute lymphoblastic leukemia

|Clinical and Experimental Medicine|2023|11

A surrogate molecular approach for the detection of Philadelphia chromosome–like B‐acute lymphoblastic leukemia

|Cancer|2023|11